U.S. pharma huge copyright scrapped two experimental weight loss drugs last year—a when-every day capsule, lotiglipron, because of elevated liver enzymes and also a 2 times-daily capsule, danuglipron, because of solid Unwanted effects—but CEO Albert Bourla has said the company is determined to “play and win” inside the obesity Room As well